Smarter research & development to tackle global health priorities
WHO's new Science Division launched an online resource to guide the development of new health products for which there are limited markets or incentives for research and development. An essential tool for realizing universal health coverage, the Health Product Profile Directory, is aimed at promoting research and development for products to combat neglected diseases and threats to global health,.... read more
Pool Chemical Injuries Lead to Over 4,000 ED Visits Each Year: CDC
Pool chemical injuries led to 4,535 U.S. emergency department visits annually during 2008-2017, revealed a report published in CDC's Morbidity and Mortality Weekly Report. Pool chemicals kill germs in the water but can harm people if mishandled.
While injuries from pool chemicals are preventable, the number of serious injuries from these chemicals has not shown much change over the last 15 years..... read more
In 4 years, severest form of TB strikes 55 in Pune
A total of 55 cases of the extensively drug-resistant tuberculosis (XDR-TB) - the world's most untreatable form of TB - have been detected within the municipal limits of Pune in a little over four years, between January 2015 and March 2019, revealed the latest report of the Pune Municipal Corporation's health department..... read more
U.S. Recorded 75 New Measles Cases Last Week
The United States recorded 75 new measles cases last week, bringing the number of confirmed cases for the year so far to 839, the worst outbreak since 1994, said federal health officials.
The U.S. Centers for Disease Control and Prevention reported that the number of cases of the highly contagious and sometimes fatal disease rose by 9.8% in the week ended May 10.... read more
Zilucoplan May Decrease Symptoms of Generalized Myasthenia Gravis
The novel peptide inhibitor zilucoplan is safe and effective in treating patients with generalized myasthenia gravis (gMG), suggests new research.
A randomized, double-blind phase 2 trial of 44 patients with gMG revealed that those who received zilucoplan 0.3 mg/kg daily for 12 weeks showed a significant 6-point improvement from baseline in Quantitative Myasthenia Gravis (QMG) scores, the primary endpoint, and significantly improved scores on the MG Activities of Daily Living (MG-ADL) scale.